Sure, you already know there's an Internet gold rush currently in force. But there's also another gold rush going on — one you probably haven't heard about. Biotech companies — especially the ones involved with gene therapy and the human genome project — are stampeding to the U.S. Patent and Trademark Office patenting every scrap of DNA and genetic information possible.

In fact, about 15 DNA patents are granted every single day. Yet even with this kind of fantastic phenomenon occurring, the market has completely forgotten about biotech stocks. It's been almost a decade, and finally the biotech sector is gaining ground. Back in 1991, the biotech industry promised breakthroughs that sent shares soaring almost 150%. But this enthusiasm didn't last, and by the first five months of 1992, the sector had lost 40% of its value.

What can we expect from the recent biotech surge — another bust? No — this time it's for real. Unlike 1991, major players like Amgen (AMGN-NASDAQ), Biogen (BGEN-NASDAQ) and Genzyme (GENZ-NASDAQ) are now generating profits and have drugs on the market and in the pipeline. Many of the companies have grown up since 1991, and those infant companies trying to bring products to market, seek financing from the pharmaceutical industry and from the private and public sector. Of course there are fundamentals at work, but this hardly explains the recent race to invest in biotechs. The roots of the biotech rally can be traced back to January 1999. A series of press releases and stories about the scientific progress towards deciphering the way human genes are constructed sparked a new interest. Now that the gene map has been decoded and researchers can develop new drugs, there will be potential for explosive growth for pharmaceutical companies as well as companies that make tools for genomics.

Please join Siu-Yee Ng, Brian Hicks, James Passin and many other gurus in the industry at the Annual Cutting Edge Biotech Symposium on August 23-26 in Washington D.C. We'll give you the scoop on what we can expect from the biotech IPO market and what hot IPOs are in the pipeline. Will the current biotech boom continue, and what stocks are hot now? We'll meet with top management and learn what to look for when investing in biotechs. All these questions will be answered.

The first 25 people to register will receive The Secrets of the Rogue Trader and Better than ebay: the Hottest IPOs for the 21st Century — valued at $149. So don't delay make your reservations as soon as possible.

To book the conference or for more information, use our online reservation form or call Agora Travel immediately at 800-926-6575 or 561-243-6276; fax: 561-278-8765; email: tours@gate.net.